IMPROVING QUALITY OF LIFE AFTER OPTIMAL RADIOTHERAPY FOR INTERMEDIATE AND HIGH RISK PROSTATE CANCER: A Randomized Comparison of HDR Versus LDR BRACHYTHERAPY BOOST
Optimal non surgical treatment of prostate cancer requires dose escalation which is
frequently provided by adding a brachytherapy "boost" to a short course of external beam
radiation therapy. The hypothesis in this randomized study is that a High Dose Rate (HDR)
brachytherapy boost leads to equivalent or better Prostate Specific Antigen (PSA)
recurrence-free survival when compared to a Low Dose Rate (LDR) brachytherapy boost and that
it is associated with a more favourable toxicity profile and improved quality of life.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society